The Federal Government has confirmed the arrival of the long-acting HIV prevention injection, Lenacapavir, marking a major step in expanding the country’s HIV prevention options.
This was announced in a statement signed by Adebobola Bashorun, National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP) at the Federal Ministry of Health and Social Welfare, on Wednesday, March 11, 2026.
He noted that the introduction of the drug underscores Nigeria’s commitment to innovative and evidence-based strategies to curb new infections.
Bashorun said that the arrival of the HIV prevention vaccine, Lenacapavir, reflects Nigeria’s continued dedication to accelerating progress toward HIV epidemic control.
“NASCP, in collaboration with partners and stakeholders, will work to ensure the safe introduction, strategic deployment, and effective integration of Lenacapavir into the national HIV prevention options,” he noted.
“The rollout will support ongoing efforts to increase access to prevention services while reinforcing Nigeria’s broader HIV response,” he added.
Read Also:Fertiliser prices rise 11% fueling food inflation fears, How Nollywood documentary fuels economic revival for Chibok women
“NASCP remains committed to advancing equitable access to HIV prevention, testing, treatment, and care services.
The arrival of Long-Acting Injectable Lenacapavir is a clear demonstration of Nigeria’s resolve to scale up innovative solutions and strengthen the fight against HIV. Together, Nigeria moves closer to ending HIV as a public health threat,” he further explained.
Lenacapavir, developed by Gilead Sciences, is a long-acting injectable administered twice a year, offering a more convenient alternative to daily oral preventive medications.
Health authorities say the introduction of Lenacapavir for pre-exposure prophylaxis (PrEP) represents a significant step toward broadening prevention choices for individuals at risk of HIV infection.
“As a long-acting injectable option, LEN PrEP has the potential to improve adherence and expand access to effective HIV prevention services for populations that may face challenges with daily oral prevention options.
“By expanding prevention options and strengthening service delivery, the country is taking decisive steps to reduce new HIV infections and improve health outcomes for communities across Nigeria,” the statement further read.
The drug is expected to be available in Nigeria and 119 other low- and middle-income countries at about $40 per person annually following voluntary licensing agreements with generic manufacturers.
“This milestone, approved by the Coordinating Minister of Health and Social Welfare, Ali Pate, and supported through the Global Fund, represents a major advancement in the country’s HIV prevention efforts and further strengthens Nigeria’s commitment to expanding innovative HIV prevention options,” the statement added.
